Stryker Corporation $SYK Shares Acquired by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. boosted its stake in Stryker Corporation (NYSE:SYK) by 9.5% in the 1st quarter, Holdings Channel reports. The firm owned 15,355 shares of the medical technology company’s stock after buying an additional 1,337 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Stryker were worth $5,716,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Mogy Joel R Investment Counsel Inc. increased its holdings in Stryker by 3.4% in the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock valued at $36,561,000 after purchasing an additional 3,218 shares in the last quarter. Ferguson Wellman Capital Management Inc. increased its holdings in Stryker by 1.9% in the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock valued at $65,096,000 after purchasing an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Stryker in the 1st quarter valued at $1,840,000. Mar Vista Investment Partners LLC increased its holdings in Stryker by 10.2% in the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after purchasing an additional 8,353 shares in the last quarter. Finally, AXS Investments LLC increased its holdings in Stryker by 13.7% in the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after purchasing an additional 1,062 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Needham & Company LLC increased their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Friday, July 18th. Citigroup reissued a “buy” rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Evercore ISI upped their price objective on shares of Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Finally, Truist Financial set a $415.00 price objective on shares of Stryker and gave the company a “hold” rating in a research report on Monday, August 4th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $431.42.

Insider Transactions at Stryker

In related news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $383.22 on Thursday. The firm has a market cap of $146.51 billion, a PE ratio of 50.76, a price-to-earnings-growth ratio of 2.86 and a beta of 0.93. The firm’s 50-day simple moving average is $389.22 and its 200-day simple moving average is $379.70. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.